Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s share price gapped down before the market opened on Thursday . The stock had previously closed at $11.26, but opened at $10.92. Mesoblast shares last traded at $10.86, with a volume of 45,100 shares.
Wall Street Analysts Forecast Growth
A number of research firms have commented on MESO. Piper Sandler restated an "overweight" rating and set a $24.00 price objective (up previously from $15.00) on shares of Mesoblast in a research note on Friday, February 7th. Cantor Fitzgerald upgraded Mesoblast to a "strong-buy" rating in a research note on Monday, March 31st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $18.00.
Check Out Our Latest Research Report on MESO
Mesoblast Stock Performance
The company has a 50 day moving average price of $11.57 and a 200-day moving average price of $13.94. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21.
Hedge Funds Weigh In On Mesoblast
Several hedge funds and other institutional investors have recently modified their holdings of the business. Goldman Sachs Group Inc. bought a new position in shares of Mesoblast in the 1st quarter valued at $3,209,000. Cubist Systematic Strategies LLC increased its stake in shares of Mesoblast by 104.3% in the 1st quarter. Cubist Systematic Strategies LLC now owns 71,891 shares of the company's stock valued at $897,000 after purchasing an additional 36,700 shares during the last quarter. OLD Mission Capital LLC bought a new position in shares of Mesoblast in the 1st quarter valued at $148,000. XY Capital Ltd acquired a new stake in shares of Mesoblast during the 1st quarter valued at $346,000. Finally, Thoroughbred Financial Services LLC boosted its holdings in shares of Mesoblast by 20.9% during the 1st quarter. Thoroughbred Financial Services LLC now owns 20,718 shares of the company's stock valued at $258,000 after acquiring an additional 3,576 shares in the last quarter. Institutional investors own 1.43% of the company's stock.
Mesoblast Company Profile
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Further Reading
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
